Market Research Logo

Eosinophilic esophagitis (EoE) - Market Insights, Epidemiology and Market Forecast-2027

DelveInsight’s ‘Eosinophilic esophagitis (EoE) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of EoE in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Eosinophilic esophagitis (EoE) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Eosinophilic esophagitis (EoE) - Disease Understanding and Treatment Algorithm
The DelveInsight Eosinophilic esophagitis (EoE) market report gives the thorough understanding of Eosinophilic esophagitis (EoE) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Eosinophilic esophagitis (EoE) in the US, Europe, and Japan.

Eosinophilic esophagitis (EoE) Epidemiology
The Eosinophilic esophagitis (EoE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, Sex-Specific Prevalent cases, Age-Specific Prevalent cases and Prevalent cases by Clinical Manifestation (Dysphagia, abdominal pain, chest pain, allergic disease) scenario of Eosinophilic esophagitis (EoE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total prevalent population of Eosinophilic esophagitis (EoE) was found to be 433,358, in the year 2016 in 7MM.

Eosinophilic esophagitis (EoE) Drug Chapters
This segment of the Eosinophilic esophagitis (EoE) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, there are no FDA approved therapies for the treatment of EoE in the United States and the current therapeutic market for EoE is based on the off-label corticosteroids, mainly Fluticasone and Budesonide, which have proven their efficacy in the management of the disease over the years. Detailed chapter for upcoming therapies like SHP621 (Shire), APT-1011 (Adare Pharmaceuticals), and Dupilumab (Regeneron) have also been covered in the report.

Eosinophilic esophagitis (EoE) Market Outlook
The Eosinophilic esophagitis (EoE) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Eosinophilic esophagitis (EoE) in 7MM was found to be USD 288.09 million in 2016.

Eosinophilic esophagitis (EoE) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Eosinophilic esophagitis (EoE) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Eosinophilic esophagitis (EoE) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Eosinophilic esophagitis (EoE) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Eosinophilic esophagitis (EoE) market
• Organize sales and marketing efforts by identifying the best opportunities for Eosinophilic esophagitis (EoE) market
• To understand the future market competition in the Eosinophilic esophagitis (EoE) market.


1. Key Insights
2. Eosinophilic Esophagitis Market Overview at a Glance
2.1. Market Share (%) Distribution of Eosinophilic Esophagitis in 2017
2.2. Market Share (%) Distribution of Eosinophilic Esophagitis in 2027
3. Disease Background and Overview: Eosinophilic esophagitis (EoE)
3.1. Introduction
3.2. Pathophysiology
3.3. Causes
3.4. Risk factors
3.5. Signs and Symptoms
3.6. Clinical Manifestations
3.7. Diagnosis
3.8. Monitoring Tools
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
5. 7MM Total Prevalent Patient Population of Eosinophilic esophagitis
5.1. Country Wise-Epidemiology of Eosinophilic esophagitis (EoE)
5.2. United States
5.2.1. Total Prevalent Population of EoE in the US
5.2.2. Sex-specific Prevalence of EoE in the US
5.2.3. Age-specific prevalence of EoE in the US
5.2.4. Prevalence by Clinical Manifestation
5.3. EU5 Countries
5.4. Germany
5.4.1. Total Prevalent Population of EoE in Germany
5.4.2. Sex-specific Prevalence of EoE in Germany
5.4.3. Age-specific prevalence of EoE in Germany
5.4.4. Prevalence by Clinical Manifestation
5.5. France
5.5.1. Total Prevalent Population of EoE in France
5.5.2. Sex-specific Prevalence of EoE in France
5.5.3. Age-specific prevalence of EoE in France
5.5.4. Prevalence by Clinical Manifestation
5.6. Italy
5.6.1. Total Prevalent Population of EoE in Italy
5.6.2. Sex-specific Prevalence of EoE in Italy
5.6.3. Age-specific prevalence of EoE in Italy
5.6.4. Prevalence by Clinical Manifestation
5.7. Spain
5.7.1. Total Prevalent Population of EoE in Spain
5.7.2. Sex-specific Prevalence of EoE in Spain
5.7.3. Age-specific prevalence of EoE in Spain
5.7.4. Prevalence by Clinical Manifestation
5.8. United Kingdom
5.8.1. Total Prevalent Population of EoE in the UK
5.8.2. Sex-specific Prevalence of EoE in the UK
5.8.3. Age-specific prevalence of EoE in the UK
5.8.4. Prevalence by Clinical Manifestation
5.9. Japan
5.9.1. Total Prevalent Population of EoE in Japan
5.9.2. Sex-specific Prevalence of EoE in Japan
5.9.3. Age-specific prevalence of EoE in Japan
5.9.4. Prevalence by Clinical Manifestation
6. Current Treatment and Medical Practices
6.1. Therapeutic Options
6.2. Treatment Guidelines
6.2.1. American College of Gastroenterology: Recommendations
6.2.2. European Committee: Eosinophilic esophagitis Recommendations
6.2.3. ESPGHAN Eosinophilic esophagitis Working Group and the Gastroenterology Committee: Recommendations
7. Unmet Needs
8. Marketed drugs
8.1. Jorveza: Dr. FalkPharma
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Safety and Efficacy
8.1.6. Ongoing trial description, 2018
8.1.7. Product Profile
9. Emerging Drugs
9.1. Key Cross Competition
9.2. SHP621: Shire Plc
9.2.1. Product Description
9.2.2. Regulatory Milestones
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Advantages and Disadvantages
9.2.6. Product Profile
9.3. Dupilumab: Regeneron Pharmaceuticals, Inc. /Sanofi
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile
9.4. APT-1011: Adare Pharmaceuticals
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Clinical Development
9.4.4. Safety and Efficacy
9.4.5. Advantages and Disadvantages
9.4.6. Product Profile
10. Eosinophilic Esophagitis [EoE]: 7 Major Market Analysis
10.1. Assumptions & Rationale
10.1.1. Fluticasone vs. Budesonide [Assumptions]
10.2. Market Size of Eosinophilic Esophagitis (EoE) in 7MM
10.3. Therapy-based Market Size of Eosinophilic Esophagitis (EoE)
11. Market Outlook by Country
11.1. The United States
11.1.1. Market Outlook
11.1.2. Total Market size of EoE in the U.S.
11.1.3. Therapy-based market size of EoE in the U.S.
11.2. EU-5 Countries: Market Outlook
11.3. Germany
11.3.1. Total Market size of Eosinophilic esophagitis (EoE) in Germany
11.3.2. Therapy-based market size of EoE in Germany
11.4. France
11.4.1. Total Market size of Eosinophilic esophagitis (EoE) in France
11.4.2. Therapy-based market size of EoE in France
11.5. United Kingdom
11.5.1. Total Market size of Eosinophilic esophagitis (EoE) in the UK
11.5.2. Therapy-based market size of EoE in the UK
11.6. Spain
11.6.1. Total Market size of Eosinophilic esophagitis (EoE) in Spain
11.6.2. Therapy-based market size of EoE in Spain
11.7. Italy
11.7.1. Total Market size of Eosinophilic esophagitis (EoE) in Italy
11.7.2. Therapy-based market size of EoE in Italy
11.8. Japan
11.8.1. Market Outlook
11.8.2. Total Market size of Eosinophilic esophagitis (EoE) in Japan
11.8.3. Therapy-based market size of EoE in Japan
12. Market Drivers
13. Market Barriers
14. Appendix
14.1. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
List of Tables and Figures
Table 1: Clinical manifestations of EoE
Table 2: Endoscopic features of EoE
Table 3: Total Prevalent Patient Population of Eosinophilic Esophagitis in the 7MM (2016-2027)
Table 4: Total Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Table 5: Sex-Specific Prevalence of Eosinophilic Esophagitis in the US (2016-2027)
Table 6: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Table 7: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 8: Total Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Table 9: Sex-Specific Prevalence of Eosinophilic Esophagitis in Germany (2016-2027)
Table 10: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Table 11: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 12: Total Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Table 13: Sex-Specific Prevalence of Eosinophilic Esophagitis in France (2016-2027)
Table 14: Age Specific Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Table 15: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 16: Total Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Table 17: Sex-Specific Prevalence of Eosinophilic Esophagitis in Italy (2016-2027)
Table 18: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Italy(2016-2027)
Table 19: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 20: Total Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Table 21: Sex-Specific Prevalence of Eosinophilic Esophagitis in Spain (2016-2027)
Table 22: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Table 23: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 24: Total Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Table 25: Sex-Specific Prevalence of Eosinophilic Esophagitis in the UK (2016-2027)
Table 26: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Table 27: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 28: Total Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Table 29: Sex-Specific Prevalence of Eosinophilic Esophagitis in Japan (2016-2027)
Table 30: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Table 31: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 32: Budesonide, Clinical Trial Description, 2018
Table 33: Comparison of emerging drugs under development
Table 34: SHP-621, Clinical Trial Description, 2018
Table 35: Dupilumab, Clinical Trial Description, 2018
Table 36: APT-1011, Clinical Trial Description, 2018
Table 37: 7 Major Market Size of Eosinophilic Esophagitis (EoE) in USD Million (2016-2027)
Table 38: 7MM Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in USD Million (2016-2027)
Table 39: Market Size of Eosinophilic Esophagitis (EoE) ) in the United States, USD Million (2016-2027)
Table 40: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in in the US, in USD Million (2016-2027)
Table 41: Market Size of Eosinophilic Esophagitis (EoE) in Germany, in USD Million (2016-2027)
Table 42: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Germany, in USD Million (2016-2027)
Table 43: Market Size of Eosinophilic Esophagitis (EoE) in France, in USD Million (2016-2027)
Table 44: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in France, in USD Million (2016-2027)
Table 45: Market Size of Eosinophilic Esophagitis (EoE) in the UK, in USD Million (2016-2027)
Table 46: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in the UK, in USD Million (2016-2027)
Table 47: Market Size of Eosinophilic Esophagitis (EoE) in Spain, in USD Million (2016-2027)
Table 48: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Spain, in USD Million (2016-2027)
Table 49: Market Size of Eosinophilic Esophagitis (EoE) in Italy, in USD Million (2016-2027)
Table 50: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Italy, in USD Million (2016-2027)
Table 51: Market Size of Eosinophilic Esophagitis (EoE) in Japan, in USD Million (2016-2027)
Table 52: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Japan, in USD Million (2016-2027)
Figure 1: Pathophysiological mechanism involved in Eosinophilic infiltration of esophageal mucosa
Figure 2: Signs and Symptoms of Eosinophilic esophagitis (EoE)
Figure 3: Total Prevalent Patient Population of Eosinophilic Esophagitis in the 7MM (2016-2027)
Figure 4: Total Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Figure 5: Sex-Specific Prevalence of Eosinophilic Esophagitis in the US (2016-2027)
Figure 6: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Figure 7: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 8: Total Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Figure 9: Sex-Specific Prevalence of Eosinophilic Esophagitis in Germany (2016-2027)
Figure 10: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Figure 11: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 12: Total Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Figure 13: Sex-Specific Prevalence of Eosinophilic Esophagitis in France (2016-2027)
Figure 14: Age Specific Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Figure 15: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 16: Total Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Figure 17: Sex-Specific Prevalence of Eosinophilic Esophagitis in Italy (2016-2027)
Figure 18: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Figure 19: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 20: Total Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Figure 21: Sex-Specific Prevalence of Eosinophilic Esophagitis in Spain(2016-2027)
Figure 22: Age Specific Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Figure 23: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 24: Total Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Figure 25: Sex-Specific Prevalence of Eosinophilic Esophagitis in the UK (2016-2027)
Figure 26: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Figure 27: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 28: Total Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Figure 29: Sex-Specific Prevalence of Eosinophilic Esophagitis in Japan (2016-2027)
Figure 30: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Figure 31: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 32: General treatment of Eosinophilic Esophagitis
Table 33: Topical steroid initial dosing for treatment of Eosinophilic Esophagitis
Table 34: Treatment General Practices
Figure 35: Treatment Algorithm
Figure 37: Unmet Needs of Eosinophilic esophagitis (EoE)
Figure 38: 7 Major Market Size of Eosinophilic Esophagitis (EoE) in USD Million (2016-2027)
Figure 39: 7MM Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in USD Million (2016-2027)
Figure 40: Market Size of Eosinophilic Esophagitis (EoE) in the United States, USD Millions (2016-2027)
Figure 41: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in the US, in USD Million (2016-2027)
Figure 42: Market Size of Eosinophilic Esophagitis (EoE) in Germany, USD Millions (2016-2027)
Figure 43: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Germany, in USD Million (2016-2027)
Figure 44: Market Size of Eosinophilic Esophagitis (EoE) in France, USD Millions (2016-2027)
Figure 45: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in France, in USD Million (2016-2027)
Figure 46: Market Size of Eosinophilic Esophagitis (EoE) in the UK, USD Millions (2016-2027)
Figure 47: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in the UK, in USD Million (2016-2027)
Figure 48: Market Size of Eosinophilic Esophagitis (EoE) in Spain, USD Millions (2016-2027)
Figure 49: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in the US, in USD Million (2016-2027)
Figure 50: Market Size of Eosinophilic Esophagitis (EoE) in Italy, USD Millions (2016-2027)
Figure 51: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Italy, in USD Million (2016-2027)
Figure 52: Market Size of Eosinophilic Esophagitis (EoE) in Japan, USD Millions (2016-2027)
Figure 53: Therapy-based Market Size of Eosinophilic Esophagitis (EoE) in Japan, in USD Million (2016-2027)
Figure 54: Market Drivers
Figure 55: Market Barriers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report